AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15126928 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antihypertensive treatment in diabetic patients (n=492)
Number of subjects: 4695
Study 11200354 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification of complications from interventional procedures
Number of subjects: 193
Study 10211918 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day
Number of subjects: 42
Study 10211918 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 75 mg/day
Number of subjects: 42
Study 8582387 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed ventricular stimulation from the right ventricular apex
Number of subjects: 66
Study 8582387 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed ventricular stimulation from the outflow tract
Number of subjects: 66
Study 8582387 — intervention group
Group type: COMPARATOR
Intervention: Programmed ventricular stimulation (general)
Number of subjects: 66
Study 2197535 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g/d cotrimoxazole (TMP/SMX) i.v.
Number of subjects: 60
Study 2197535 — intervention group
Group type: COMPARATOR
Intervention: 600 mg aerosolized pentamidine
Number of subjects: 60
Study 347887 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (6 g daily) and ECT
Number of subjects: 0
Study 347887 — intervention group
Group type: COMPARATOR
Intervention: Placebo and ECT
Number of subjects: 0
Study 30124597 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (1 ng/kg)
Number of subjects: 0
Study 30124597 — intervention group
Group type: COMPARATOR
Intervention: Septic shock patients
Number of subjects: 0
Study 26420886 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (0.4 g/kg 10% IVIG every 2 weeks for a total of 5 infusions, 2 g/kg total dose)
Number of subjects: 50
Study 26420886 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 50
Study 26420886 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 50
Study 25529292 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 0
Study 25529292 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban residence and history of TB contact/disease
Number of subjects: 0
Study 25529292 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine strain, LTBI, HIV infection, asymptomatic malaria, growth z-scores, childhood anthelminthic treatment, maternal BCG scar
Number of subjects: 0
Study 25529292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine responses at one year
Number of subjects: 0
Study 23484892 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor (C1 INH‐nf; human)
Number of subjects: 16
Study 21073372 — intervention group
Group type: EXPERIMENTAL
Intervention: Irsogladine 4 mg/day
Number of subjects: 119
Study 21073372 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 40 mg/day
Number of subjects: 119
Study 19584759 — intervention group
Group type: EXPERIMENTAL
Intervention: Option 1 (EQ-5D)
Number of subjects: 389
Study 19584759 — intervention group
Group type: EXPERIMENTAL
Intervention: Option 2 (EQ-5D)
Number of subjects: 389
Study 19584759 — intervention group
Group type: EXPERIMENTAL
Intervention: Option 3 (EQ-5D)
Number of subjects: 389
Study 19584759 — intervention group
Group type: EXPERIMENTAL
Intervention: Option 3 (SF-6D)
Number of subjects: 389
Study 19584759 — intervention group
Group type: EXPERIMENTAL
Intervention: Option 2 (SF-6D)
Number of subjects: 389
Study 19584759 — intervention group
Group type: EXPERIMENTAL
Intervention: Option 1 (SF-6D)
Number of subjects: 389
Study 16758938 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Albumin (Plasbumin)
Number of subjects: 36
Study 16758938 — intervention group
Group type: COMPARATOR
Intervention: 4% Succinylated gelatin (helofusin)
Number of subjects: 36
Study 15116294 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin administered as an infusion of 500 mg/h for 1.5 h (total dose, 750 mg) with additional drugs for specific pathogens (ceftazidime or piperacillin/tazobactam for P. aeruginosa and vancomycin for methicillin-resistant S. aureus).
Number of subjects: 58
Study 11501226 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9141217 — intervention group
Group type: EXPERIMENTAL
Intervention: Imule system (needleless jet-injector)
Number of subjects: 0
Study 9141217 — intervention group
Group type: COMPARATOR
Intervention: Standard syringe technique
Number of subjects: 0
Study 8426211 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial therapy with floxuridine, mitomycin, and carmustine (FMB)
Number of subjects: 95
Study 8426211 — intervention group
Group type: COMPARATOR
Intervention: Hepatic arterial therapy with floxuridine alone (F)
Number of subjects: 95
Study 8426211 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 95
Study 6150140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gammaglobulin prepared by Cohn fractionation of pooled plasma
Number of subjects: 12
Study 31264762 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FVIII (rFVIII)
Number of subjects: 54
Study 31264762 — intervention group
Group type: COMPARATOR
Intervention: plasma-derived FVIII (pdFVIII)
Number of subjects: 54
Study 31264762 — intervention group
Group type: EXPERIMENTAL
Intervention: SIPPET study findings
Number of subjects: 54
Study 29509293 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 6
Study 29509293 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 6
Study 29509293 — intervention group
Group type: COMPARATOR
Intervention: Control (gutta-percha)
Number of subjects: 6
Study 26166213 — intervention group
Group type: EXPERIMENTAL
Intervention: Episode transmitting a prevention message
Number of subjects: 208
Study 26166213 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterarguing
Number of subjects: 208
Study 24577097 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day of phosphatidylserine enriched with docosahexaenoic acid (PS-DHA)
Number of subjects: 122
Study 22337277 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction group (received infusion with fresh-frozen plasma and/or platelets)
Number of subjects: 72
Study 22337277 — intervention group
Group type: COMPARATOR
Intervention: No correction group (no transfusion)
Number of subjects: 72
Study 20559006 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (DL) 5 mg once daily
Number of subjects: 716
Study 20559006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 716
Study 17991266 — intervention group
Group type: EXPERIMENTAL
Intervention: Single use LMA Flexible
Number of subjects: 100
Study 17991266 — intervention group
Group type: COMPARATOR
Intervention: Reusable LMA Flexible
Number of subjects: 100
Study 16458655 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal supplements with 30 mg of iron as ferrous sulfate (n = 218 women)
Number of subjects: 429
Study 16458655 — intervention group
Group type: COMPARATOR
Intervention: 0 mg of iron (control group, n = 211 women)
Number of subjects: 429
Study 15542241 — intervention group
Group type: EXPERIMENTAL
Intervention: Phobia-related words
Number of subjects: 0
Study 15542241 — intervention group
Group type: COMPARATOR
Intervention: Phobia-unrelated words
Number of subjects: 0
Study 11081593 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 51
Study 11081593 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine
Number of subjects: 51
Study 8889421 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium (1 mg kg‐1)
Number of subjects: 11
Study 8889421 — intervention group
Group type: COMPARATOR
Intervention: saline (0.02 mL kg‐1)
Number of subjects: 11
Study 2005165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented Thompson stem
Number of subjects: 53
Study 2005165 — intervention group
Group type: COMPARATOR
Intervention: Uncemented Austin Moore stem
Number of subjects: 53
Study 6435961 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Lysine monohydrochloride 1,248 mg/day
Number of subjects: 41
Study 6435961 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Lysine monohydrochloride 624 mg/day
Number of subjects: 41
Study 6435961 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Lysine monohydrochloride (both dosages)
Number of subjects: 41
Study 6435961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31009578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive periodontal treatment
Number of subjects: 21
Study 31009578 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (6-month delay in treatment)
Number of subjects: 21
Study 27179286 — intervention group
Group type: EXPERIMENTAL
Intervention: ¡Cocinar Para Su Salud! (Cook for Your Health!) dietary intervention
Number of subjects: 0
Study 26117247 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Treatment Adherence Program
Number of subjects: 30
Study 26117247 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Assessment and Monitoring
Number of subjects: 30
Study 23623047 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan at 20 mg/day
Number of subjects: 100
Study 23623047 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan at 80 mg/day
Number of subjects: 100
Study 20955210 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fenoldopam infusion
Number of subjects: 17
Study 20955210 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 17
Study 19164400 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (exercise training twice weekly for 12 weeks, nutritional and self-care advice, education about disease and energy conservation)
Number of subjects: 30
Study 19164400 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 30
Study 19164400 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 16676703 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum supplementation
Number of subjects: 35
Study 16676703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 15526230 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA fluorescence detection
Number of subjects: 115
Study 15526230 — intervention group
Group type: COMPARATOR
Intervention: White light cystoscopy
Number of subjects: 115
Study 11009285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue harmonic imaging
Number of subjects: 40
Study 11009285 — intervention group
Group type: COMPARATOR
Intervention: Standard echocardiographic assessment
Number of subjects: 40
Study 9279337 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (extended duration by an additional five years)
Number of subjects: 0
Study 9279337 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (standard duration)
Number of subjects: 0
Study 8377777 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum sunscreen cream with SPF 17
Number of subjects: 588
Study 8377777 — intervention group
Group type: COMPARATOR
Intervention: Base cream (control)
Number of subjects: 588
Study 3535685 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator (salbutamol)
Number of subjects: 8
Study 3535685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 27855541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 41
Study 27855541 — intervention group
Group type: COMPARATOR
Intervention: Behavioral Therapy (BT)
Number of subjects: 41
Study 27357583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionator or Activator followed by fixed appliances
Number of subjects: 40
Study 27357583 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated Class II malocclusion)
Number of subjects: 40
Study 24722498 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 2425
Study 24722498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2425
Study 22712373 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA)
Number of subjects: 60
Study 20420955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural intervention; details on dosage and duration not specified.
Number of subjects: 0
Study 20420955 — intervention group
Group type: COMPARATOR
Intervention: Control group; details not specified.
Number of subjects: 0
Study 18400466 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation condition (third party observer present)
Number of subjects: 70
Study 18400466 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no observer present)
Number of subjects: 70
Study 16524126 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% (Travatan)
Number of subjects: 27
Study 16524126 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (Xalatan)
Number of subjects: 27
Study 11642644 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education and high‐intensity strength intervention
Number of subjects: 0
Study 11642644 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9647369 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal duodenal mucosa (n = 26)
Number of subjects: 126
Study 9647369 — intervention group
Group type: EXPERIMENTAL
Intervention: Scallops and grooves (n = 7)
Number of subjects: 126
Study 9647369 — intervention group
Group type: EXPERIMENTAL
Intervention: Scallops alone (n = 4)
Number of subjects: 126
Study 9647369 — intervention group
Group type: EXPERIMENTAL
Intervention: Grooves alone (n = 3)
Number of subjects: 126
Study 9647369 — intervention group
Group type: COMPARATOR
Intervention: Normal duodenum (n = 100)
Number of subjects: 126
Study 7853452 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation (VS) strength training for the arms and conventional stretching exercises for the legs
Number of subjects: 28
Study 7853452 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional exercises for strength of the arms and VS stretching exercises for the legs
Number of subjects: 28
Study 7853452 — intervention group
Group type: COMPARATOR
Intervention: Irrelevant training (control group)
Number of subjects: 28
Study 7853452 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation (VS) flexibility training
Number of subjects: 28
Study 7853452 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional training
Number of subjects: 28
Study 2685660 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of gangliosides (Cronassial)
Number of subjects: 40
Study 2685660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 954734 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive, step increment, discontinuous tests (DCT)
Number of subjects: 10
Study 954734 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive, step increment, continuous test (CT)
Number of subjects: 10
Study 954734 — intervention group
Group type: COMPARATOR
Intervention: Constant load tests (CL and CL + 2 1/2%)
Number of subjects: 10
Study 954734 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous and continuous progressive tests
Number of subjects: 10
Study 31526874 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II trials
Number of subjects: 57
Study 31526874 — intervention group
Group type: COMPARATOR
Intervention: Phase III trials
Number of subjects: 57
Study 28278194 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral tissue sensing (STS)
Number of subjects: 19
Study 25337948 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-delivered cognitive behavior therapy (ICBT) for insomnia
Number of subjects: 43
Study 25337948 — intervention group
Group type: COMPARATOR
Intervention: Guided Internet-delivered cognitive behavior therapy (ICBT) for depression
Number of subjects: 43
Study 23037929 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan's technique
Number of subjects: 40
Study 23037929 — intervention group
Group type: COMPARATOR
Intervention: Passive stretching exercises
Number of subjects: 40
Study 22133239 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised muscle strengthening, flexibility, and endurance training (60 minutes, 3 times per week for 2 months)
Number of subjects: 75
Study 22133239 — intervention group
Group type: COMPARATOR
Intervention: No direct intervention (Control group)
Number of subjects: 75
Study 20079223 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic Orlistat 120 mg 3 times a day with an energy-controlled diet for 24 weeks
Number of subjects: 228
Study 20079223 — intervention group
Group type: COMPARATOR
Intervention: Imported Orlistat 120 mg 3 times a day with an energy-controlled diet for 24 weeks
Number of subjects: 228
Study 16395076 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune enhancing (IE) diet
Number of subjects: 40
Study 16395076 — intervention group
Group type: COMPARATOR
Intervention: Regular formula
Number of subjects: 40
Study 14991119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystectomy for non-urothelial indications
Number of subjects: 42
Study 14991119 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy for transitional cell cancer of the bladder
Number of subjects: 42
Study 10943576 — intervention group
Group type: EXPERIMENTAL
Intervention: GyneFix IUD
Number of subjects: 313
Study 10943576 — intervention group
Group type: COMPARATOR
Intervention: TCu380A IUD
Number of subjects: 313
Study 8823584 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-quadrant sub-Tenon's anesthesia (1-QST)
Number of subjects: 570
Study 8823584 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 570
Study 1309865 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA (1050 mg/m2 per day for 5 days)
Number of subjects: 19
Study 1309865 — intervention group
Group type: COMPARATOR
Intervention: CaNa2EDTA (1000 mg/m2 per day intravenously)
Number of subjects: 19
Study 1309865 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA (350 or 700 mg/m2 per day for 14 days on outpatient basis)
Number of subjects: 19
Study 6331037 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg naloxone
Number of subjects: 8
Study 6331037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6331037 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg naloxone
Number of subjects: 8
Study 6331037 — intervention group
Group type: COMPARATOR
Intervention: 4.8 mg naloxone
Number of subjects: 8
Study 30193845 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 60
Study 30193845 — intervention group
Group type: COMPARATOR
Intervention: SHAM condition
Number of subjects: 60
Study 26044855 — intervention group
Group type: EXPERIMENTAL
Intervention: FAHF‐2 (n = 46)
Number of subjects: 68
Study 26044855 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 68
Study 23991522 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback and explanation
Number of subjects: 33
Study 23991522 — intervention group
Group type: COMPARATOR
Intervention: Feedback
Number of subjects: 33
Study 23991522 — intervention group
Group type: COMPARATOR
Intervention: Explanation
Number of subjects: 33
Study 23991522 — intervention group
Group type: COMPARATOR
Intervention: Feedback researcher explains
Number of subjects: 33
Study 23991522 — intervention group
Group type: COMPARATOR
Intervention: Feedback child explains
Number of subjects: 33
Study 21421768 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding confederate
Number of subjects: 0
Study 21421768 — intervention group
Group type: COMPARATOR
Intervention: Sexualized breast condition
Number of subjects: 0
Study 21421768 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 0
Study 18344081 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam/morphine
Number of subjects: 100
Study 18344081 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 100
Study 16369704 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 surgery
Number of subjects: 221
Study 16369704 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 221
Study 16369704 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal dissection
Number of subjects: 221
Study 14555566 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Expiratory Muscle Training (SEMT)
Number of subjects: 32
Study 14555566 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Inspiratory Muscle Training (SIMT)
Number of subjects: 32
Study 14555566 — intervention group
Group type: EXPERIMENTAL
Intervention: SEMT + SIMT
Number of subjects: 32
Study 14555566 — intervention group
Group type: COMPARATOR
Intervention: Control group (very low load training)
Number of subjects: 32
Study 10700888 — intervention group
Group type: EXPERIMENTAL
Intervention: M-VAC (MTX + VBL + ADM + CDDP)
Number of subjects: 0
Study 10700888 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant or adjuvant cisplatin-based regimens
Number of subjects: 0
Study 10700888 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with interferon or interleukin-2
Number of subjects: 0
Study 10700888 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant interferon-alpha administration
Number of subjects: 0
Study 10700888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based treatment protocols
Number of subjects: 0
Study 10700888 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with autologous stem-cell support
Number of subjects: 0
Study 10700888 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal androgen blockade
Number of subjects: 0
Study 10700888 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen depletion treatment
Number of subjects: 0
Study 8683544 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise interventions
Number of subjects: 11
Study 1890264 — intervention group
Group type: EXPERIMENTAL
Intervention: Food challenges
Number of subjects: 11
Study 1890264 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenges
Number of subjects: 11
Study 6362585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibronectin-rich plasma cryoprecipitate (2.139 +/‐ 0.161 mg/ml)
Number of subjects: 14
Study 6362585 — intervention group
Group type: COMPARATOR
Intervention: Fibronectin-poor cryoprecipitate extracted plasma (placebo, 0.116 +/‐ 0.025 mg/ml)
Number of subjects: 14